Literature DB >> 19498461

Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.

D Dingli1, C Offord, R Myers, K-W Peng, T W Carr, K Josic, S J Russell, Z Bajzer.   

Abstract

Replication-competent viruses are being tested as tumor therapy agents. The fundamental premise of this therapy is the selective infection of the tumor cell population with the amplification of the virus. Spread of the virus in the tumor ultimately should lead to eradication of the cancer. Tumor virotherapy is unlike any other form of cancer therapy as the outcome depends on the dynamics that emerge from the interaction between the virus and tumor cell populations both of which change in time. We explore these interactions using a model that captures the salient biological features of this system in combination with in vivo data. Our results show that various therapeutic outcomes are possible ranging from tumor eradication to oscillatory behavior. Data from in vivo studies support these conclusions and validate our modeling approach. Such realistic models can be used to understand experimental observations, explore alternative therapeutic scenarios and develop techniques to optimize therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498461      PMCID: PMC2821809          DOI: 10.1038/cgt.2009.40

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  35 in total

1.  Mathematical modeling of cancer radiovirotherapy.

Authors:  David Dingli; Matthew D Cascino; Kresimir Josić; Stephen J Russell; Zeljko Bajzer
Journal:  Math Biosci       Date:  2005-12-22       Impact factor: 2.144

2.  Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor.

Authors:  David Dingli; Brad J Kemp; Michael K O'Connor; John C Morris; Stephen J Russell; Val J Lowe
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

3.  Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.

Authors:  Hooi Tin Ong; Michael M Timm; Philip R Greipp; Thomas E Witzig; Angela Dispenzieri; Stephen J Russell; Kah-Whye Peng
Journal:  Exp Hematol       Date:  2006-06       Impact factor: 3.084

Review 4.  Viruses as anticancer drugs.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

5.  A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.

Authors:  Cari J McDonald; Charles Erlichman; James N Ingle; Gabriela A Rosales; Cory Allen; Suzanne M Greiner; Mary E Harvey; Paula J Zollman; Stephen J Russell; Evanthia Galanis
Journal:  Breast Cancer Res Treat       Date:  2006-04-27       Impact factor: 4.872

6.  Interaction of measles virus vectors with Auger electron emitting radioisotopes.

Authors:  David Dingli; Kah-Whye Peng; Mary E Harvey; Sompong Vongpunsawad; Elizabeth R Bergert; Robert A Kyle; Roberto Cattaneo; John C Morris; Stephen J Russell
Journal:  Biochem Biophys Res Commun       Date:  2005-11-11       Impact factor: 3.575

7.  Herpes oncolytic therapy of salivary gland carcinomas.

Authors:  Vincent Reid; Zhenkun Yu; Theodore Schuman; Sen Li; Paramjeet Singh; Yuman Fong; Richard J Wong
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

8.  Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.

Authors:  K-W Peng; E M Hadac; B D Anderson; R Myers; M Harvey; S M Greiner; D Soeffker; M J Federspiel; S J Russell
Journal:  Cancer Gene Ther       Date:  2006-03-10       Impact factor: 5.987

Review 9.  Immunodeficiency and immunotherapy in multiple myeloma.

Authors:  Guy Pratt; Oliver Goodyear; Paul Moss
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

Review 10.  Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.

Authors:  Robert M Lorence; M Scot Roberts; James D O'Neil; William S Groene; Jeffrey A Miller; Stephen N Mueller; Michael K Bamat
Journal:  Curr Cancer Drug Targets       Date:  2007-03       Impact factor: 3.428

View more
  20 in total

1.  Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

Authors:  Amber Miller; Rebecca Nace; Camilo Ayala-Breton C; Michael Steele; Kent Bailey; Kah Whye Peng; Stephen J Russell
Journal:  Mol Ther       Date:  2015-12-09       Impact factor: 11.454

2.  Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.

Authors:  Bella Patel; Aditi Dey; Ehsan Ghorani; Shaji Kumar; Yogeshkumar Malam; Lena Rai; Andrew J Steele; Jennifer Thomson; R Gitendra Wickremasinghe; Yu Zhang; Anna Z Castleton; Adele K Fielding
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

3.  In Vivo Estimation of Oncolytic Virus Populations within Tumors.

Authors:  Mi-Yeon Jung; Chetan P Offord; Matthew K Ennis; Iris Kemler; Claudia Neuhauser; David Dingli
Journal:  Cancer Res       Date:  2018-08-16       Impact factor: 12.701

Review 4.  Attenuated oncolytic measles virus strains as cancer therapeutics.

Authors:  P Msaouel; I D Iankov; A Dispenzieri; E Galanis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

5.  Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.

Authors:  D M Rommelfanger; C P Offord; J Dev; Z Bajzer; R G Vile; D Dingli
Journal:  Gene Ther       Date:  2011-09-15       Impact factor: 5.250

Review 6.  Computational modeling approaches to the dynamics of oncolytic viruses.

Authors:  Dominik Wodarz
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-03-22

7.  Measles virus causes immunogenic cell death in human melanoma.

Authors:  O G Donnelly; F Errington-Mais; L Steele; E Hadac; V Jennings; K Scott; H Peach; R M Phillips; J Bond; H Pandha; K Harrington; R Vile; S Russell; P Selby; A A Melcher
Journal:  Gene Ther       Date:  2011-12-15       Impact factor: 5.250

8.  Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches.

Authors:  Dominik Wodarz; Andrew Hofacre; John W Lau; Zhiying Sun; Hung Fan; Natalia L Komarova
Journal:  PLoS Comput Biol       Date:  2012-06-14       Impact factor: 4.475

9.  Computational modeling of interactions between multiple myeloma and the bone microenvironment.

Authors:  Yan Wang; Peter Pivonka; Pascal R Buenzli; David W Smith; Colin R Dunstan
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

10.  Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory.

Authors:  Mark Gluzman; Jacob G Scott; Alexander Vladimirsky
Journal:  Proc Biol Sci       Date:  2020-04-22       Impact factor: 5.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.